Clinical Trials Browser

Recruiting × Urogenital Neoplasms × pembrolizumab × Clear all

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03412877 2026-05-29

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2 Recruiting

285 enrolled

BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT07566156 2026-05-11

EV-309

Phase 3 Recruiting

390 enrolled

Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT06353906 2025-12-08

PRIAM

Phase 2 Recruiting

27 enrolled

Genitourinary

Penile Neoplasms, Urogenital Neoplasms, Urologic Neoplasms, Male Urogenital Diseases

NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Phase 2 Recruiting

24 enrolled

GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

Clinical Trials

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

EV-309

PRIAM

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer